[go: up one dir, main page]

AR066132A1 - Factor viii recombinante demanosilado para el tratamiento de pacientes con hemofilia a - Google Patents

Factor viii recombinante demanosilado para el tratamiento de pacientes con hemofilia a

Info

Publication number
AR066132A1
AR066132A1 ARP080101635A ARP080101635A AR066132A1 AR 066132 A1 AR066132 A1 AR 066132A1 AR P080101635 A ARP080101635 A AR P080101635A AR P080101635 A ARP080101635 A AR P080101635A AR 066132 A1 AR066132 A1 AR 066132A1
Authority
AR
Argentina
Prior art keywords
factor viii
demanosilated
hemophilia
patients
treatment
Prior art date
Application number
ARP080101635A
Other languages
English (en)
Inventor
Abdessatar Chtourou
Emmanuel Nony
Nicolas Bihoreau
Original Assignee
Lfb Biotechnologies
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies, Inst Nat Sante Rech Med filed Critical Lfb Biotechnologies
Publication of AR066132A1 publication Critical patent/AR066132A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporciona un factor VIII desmanosilado con inmunogenicidad, en humanos, reducida o abolida. Se describe el factor VIII modificado junto con la secuencia aminoacídica modificada, cambiada con al menos una sustitucion acido nucleico, vectorcélula y organismo transgénico no humano en posicion 239 y/o 2118 el factor VIII modificado es util en hemofílicos, para evitar o prevenir la accion de anticuerpos anti FVIII inhibidores.
ARP080101635A 2007-04-20 2008-04-18 Factor viii recombinante demanosilado para el tratamiento de pacientes con hemofilia a AR066132A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07290495A EP1985631A1 (en) 2007-04-20 2007-04-20 Demannosylated recombinant factor VIII for the treatment of patients with hemophiila A

Publications (1)

Publication Number Publication Date
AR066132A1 true AR066132A1 (es) 2009-07-22

Family

ID=38515425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101635A AR066132A1 (es) 2007-04-20 2008-04-18 Factor viii recombinante demanosilado para el tratamiento de pacientes con hemofilia a

Country Status (15)

Country Link
US (1) US8802620B2 (es)
EP (2) EP1985631A1 (es)
JP (1) JP2010524453A (es)
KR (1) KR20100017142A (es)
CN (1) CN101970481A (es)
AR (1) AR066132A1 (es)
AT (1) ATE530575T1 (es)
AU (1) AU2008240663A1 (es)
BR (1) BRPI0810592A2 (es)
CA (1) CA2684834A1 (es)
DK (1) DK2150561T3 (es)
ES (1) ES2376022T3 (es)
PL (1) PL2150561T3 (es)
TW (1) TW200914608A (es)
WO (1) WO2008129422A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102137935A (zh) * 2008-06-25 2011-07-27 拜耳医药保健有限公司 具有降低的免疫原性的因子viii突变蛋白
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
US20160207977A1 (en) * 2013-06-12 2016-07-21 Novo Nordisk A/S Compounds Suitable for Treatment of Haemophilia
AU2014339034A1 (en) 2013-10-22 2016-05-19 Dbv Technologies Method of treating haemophilia by inducing tolerance to blood factors
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
WO2016127057A1 (en) * 2015-02-06 2016-08-11 The University Of North Carolina At Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
CN108473976B (zh) * 2015-10-28 2022-07-19 桑格摩生物治疗股份有限公司 肝特异性构建体、因子viii表达盒及其使用方法
KR102175878B1 (ko) * 2016-06-24 2020-11-06 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
EP3755795A4 (en) * 2018-02-19 2022-07-20 Homology Medicines, Inc. Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
CN112575034B (zh) * 2019-09-29 2023-04-25 济南赛尔生物科技股份有限公司 一种治疗a型血友病的产品及应用
CN113248594B (zh) * 2021-04-26 2022-08-30 北京美康基免生物科技有限公司 一种重组凝血因子viii及其应用
US20240254197A1 (en) * 2021-11-25 2024-08-01 Sichuan Real&Best Biotech Co., Ltd. Engineered Human FVIII with Enhanced Secretion Ability and Clotting Activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
CA2349468C (en) * 1998-11-10 2013-07-09 Baxter Aktiengesellschaft Factor viii polypeptide having factor viii:c activity
WO2002096454A1 (en) * 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2005046583A2 (en) * 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods

Also Published As

Publication number Publication date
BRPI0810592A2 (pt) 2014-10-21
JP2010524453A (ja) 2010-07-22
EP2150561A1 (en) 2010-02-10
CA2684834A1 (en) 2008-10-30
ES2376022T3 (es) 2012-03-08
EP1985631A1 (en) 2008-10-29
ATE530575T1 (de) 2011-11-15
CN101970481A (zh) 2011-02-09
AU2008240663A1 (en) 2008-10-30
US8802620B2 (en) 2014-08-12
WO2008129422A1 (en) 2008-10-30
PL2150561T3 (pl) 2012-03-30
US20100197578A1 (en) 2010-08-05
DK2150561T3 (da) 2011-12-19
EP2150561B1 (en) 2011-10-26
TW200914608A (en) 2009-04-01
KR20100017142A (ko) 2010-02-16
WO2008129422A8 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
AR066132A1 (es) Factor viii recombinante demanosilado para el tratamiento de pacientes con hemofilia a
NL300808I2 (nl) susoctocog alfa
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2533874T3 (es) Armazón proteico
CY1112490T1 (el) Σταθεροποιητες για εμβολια ξηρανθεντα δια καταψυξεως
WO2005046583A3 (en) Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
IN2012DN00248A (es)
DK2190473T3 (da) Peptid med reduceret dimerdannelse
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
ES2688623T3 (es) Proteínas de fusión que se unen a factores de crecimiento
JP2015519313A5 (es)
PE20131034A1 (es) El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isomero posicional
PE20090225A1 (es) Proteinas de fusion que degradan el peptido beta amiloide
CU23608A3 (es) Vacuna para la tuberculosis ureasa deficiente con eficacia mejorada
ATE529123T1 (de) Synthetische glykolipopeptide als impfstoffe
BR0308860A (pt) Fator viii modificado
ES2506168T3 (es) Polipéptido que tiene actividad antibacteriana y actividad que induce la angiogénesis y fármacos que contienen dicho polipéptido que curan heridas
BR112015024609A2 (pt) proteína tendo atividade de xilose isomerase e utilização da mesma
NZ594268A (en) Grass peptides for vaccine
EA201171430A1 (ru) Пептиды
DE602006014530D1 (de) Pharmazeutisch aktive diazepane
ATE531730T1 (de) Immunogene hybridpolypeptide mit wirkung gegen obesitas und diese enthaltende impstoffzusammensetzung mit wirkung gegen obesitas
BRPI0721746A2 (pt) "polipeptídeo isolado, vacina, ácido nucléico isolado, vetor e célula transformada"

Legal Events

Date Code Title Description
FA Abandonment or withdrawal